ANCA associates vasculitis: emerging challenges and new therapeutics

1. Introduction 2. Overview of ANCA-associated Vasculitis 2.1 Definition and Classification 2.2 Epidemiology and Demographics 2.3 Pathogenesis and Pathophysiology 3. Clinical Presentation and Diagnosis 3.1 Symptoms and Signs 3.2 Diagnostic Criteria 3.3 Differential Diagnosis 4. Traditional Treatment Approaches 4.1 Immunosuppressive Therapy 4.2 Plasma Exchange 4.3 Treatment Outcomes and Limitations 5. Emerging Challenges in Management 5.1 Treatment-Resistant Cases 5.2 Long-term Complications 5.3 Patient Quality of Life 6. New Therapeutic Developments 6.1 Biologics and Small Molecules 6.2 Targeted Therapies 6.3 Gene Therapy Prospects 7. Clinical Trials and Research Directions 7.1 Ongoing Clinical Trials 7.2 Biomarkers and Prognostic Tools 7.3 Future Research Opportunities 8. Conclusion and Future Perspectives 8.1 Summary of Key Findings 8.2 Future Therapeutic Strategies 8.3 Implications for Clinical Practice

1. How do emerging biologic and small molecule therapies compare to traditional immunosuppressive treatments in terms of efficacy and safety for managing ANCA-associated vasculitis? 2. What are the key challenges and potential solutions in the application of gene therapy for the treatment of refractory ANCA-associated vasculitis cases?